Study guide

13.2 Potential Fraud, Misconduct and Evidence Preservation

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

13.2 Potential Fraud, Misconduct and Evidence Preservation

Key Takeaways Explain This Topic AI

An anomaly warrants evidence-based investigation rather than an automatic misconduct verdict.

Potentially significant integrity concerns need prompt appropriate escalation.

Preserve source and metadata without unauthorised seizure, disclosure or deletion.

Last updated: October 2026

Potential Fraud, Misconduct and Evidence Preservation

Fabrication creates data or activities that did not occur; falsification manipulates records or processes so they misrepresent what happened. Examples can include invented visits, altered eligibility results, forged signatures or intentionally omitted safety information. The ECO requires recognising and reporting potential fraud and misconduct. A CRA's duty is to protect participants, preserve reliable evidence and escalate appropriately, not to conduct an unauthorised criminal investigation.

Many anomalies have innocent explanations. Repeated rounded values can reflect the instrument display or recording convention. A late electronic entry may be a delayed transcription from contemporaneous source. An identical visit time may be an imported default. These explanations still need verification when the data are important. Avoid both dismissing a pattern because staff are friendly and declaring fraud solely from a dashboard signal.

Signals deserving investigation

Records show assessments at a time when the facility or instrument was unavailable.

An entry was changed after randomisation to satisfy an eligibility threshold without supporting source.

Signatures appear inconsistent with attribution or staff acknowledge using another person's account.

A site has unexpectedly uniform endpoint values or very low safety reporting after relevant exposure.

Product, laboratory or participant tracking records contradict a claimed visit.

Original records repeatedly cannot be produced while clean summaries are offered instead.

Each signal points to a question, not an automatic diagnosis. Establish the relevant protocol requirement, source location, timestamps, responsible person and available corroborating evidence. Preserve the distinction between what you observed, what someone reported and what remains uncertain. An objective description such as an unsupported post-randomisation value change is more useful than a speculative accusation.

Immediate priorities

If participants may face an immediate risk, involve the investigator and sponsor's urgent clinical/quality contacts without waiting to finish a routine visit report. The investigator handles medical care; the sponsor determines wider trial measures and appropriate notifications. Preserve the relevant records and system evidence under authorised procedures, maintaining privacy and blinding. Do not remove original charts, seize devices or copy identifying information to a personal account.

Inform the designated clinical management and quality functions according to the escalation plan. A serious data-integrity concern can require independent QA or another specialised review. The monitor should not promise confidentiality that prevents required reporting, bargain to suppress a concern or warn people to delete embarrassing records before an audit.

Reconstructing a questionable visit

Suppose a source note claims a timed assessment on Saturday morning, but the imaging system shows no corresponding study and the site was apparently closed. Review the actual source locations, appointment record, instrument output, acquisition metadata and any authorised alternate facility. Ask neutral questions about the discrepancy. The assessment could have occurred elsewhere or the date could be a transcription error; neither should be assumed without evidence.

If a supported correction is needed, it should preserve the original entry, actual correction date, attribution and reason. If the assessment cannot be verified, document that limitation and escalate the impact for appropriate evaluation. Recreating a clean worksheet from memory does not establish that a critical endpoint was measured at the required time.

Evidence preservation and controlled access

Electronic records include relevant metadata, access logs, version history and audit trails. A screenshot may fail to preserve context or become an uncontrolled disclosure. Use the responsible system and quality functions to retain appropriate evidence. Record what was reviewed and how it can be retrieved. Do not disable a user account yourself unless that is within your actual authority; facilitate prompt containment through the designated administrator.

For paper records, maintain originals and traceable copies as appropriate. Never discard a page because a corrected version is easier to read. Late documentation should clearly distinguish the historical event from the current entry. A properly labelled late entry can be legitimate; backdating to create a false history is not a correction.

Sponsor and investigator response

E6(R3) expects significant noncompliance to prompt appropriate action, root-cause evaluation and remediation, with relevant notifications under applicable requirements. If significant noncompliance persists despite efforts to remediate it, the sponsor should consider terminating the site or service provider's participation and minimise the impact on participants and reliable results. A fixed five-step escalation ladder must not delay an urgent response.

A final decision should evaluate the affected records, participants, processes and possibly other studies or sites. Corrective actions may address supervision, access controls, staffing, tools or incentives, but retraining alone cannot establish that already questionable data are reliable. Follow-up should verify both implementation and effectiveness using objective evidence.

Applying the lesson to exam choices

Prefer an answer that documents facts, protects participants, preserves records and promptly involves the appropriate sponsor/investigator functions. Reject backdating, quiet deletion, automatic manufacture of missing data and unsupported accusations. The professional boundary is active oversight with evidence and escalation, supported by transparency even when the finding is uncomfortable or threatens a recruitment milestone.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) , ACRP CCRA Exam Content Outline .